Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02353468 · OUTCOME

Event Free Survival Rates by Land-mark Analysis

Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant · Source last updated 2015-03-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
up to 5 years

What was measured

A Kaplan-Meier curve would have been used to describe the distribution.

Analysis population: The study was terminated, study endpoints were not reached.

Groups in this outcome

Enzyme Inhibitor, Biological Therapy, Chemotherapy

CONSOLIDATION: Patients received VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity. In between courses of VLD, patients received LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days. MAINTENANCE: Starting in the third year of therapy, patients received lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Bortezomib: Given IV Lenalidomide: Given PO Dexamethasone: Given PO or IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Enzyme Inhibitor, Biological Therapy, Chemotherapy0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
A Kaplan-Meier curve would have been used to describe the distribution.
groups
  1. description
    CONSOLIDATION: Patients received VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity. In between courses of VLD, patients received LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days. MAINTENANCE: Starting in the third year of therapy, patients received lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Bortezomib: Given IV Lenalidomide: Given PO Dexamethasone: Given PO or IV
    id
    OG000
    title
    Enzyme Inhibitor, Biological Therapy, Chemotherapy
population Description
The study was terminated, study endpoints were not reached.
reporting Status
POSTED
time Frame
up to 5 years
title
Event Free Survival Rates by Land-mark Analysis
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice